Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aura Biosciences (AURA) Accumulated Expenses (2020 - 2026)

Aura Biosciences filings provide 7 years of Accumulated Expenses readings, the most recent being $10.9 million for Q1 2026.

  • Quarterly Accumulated Expenses rose 55.56% to $10.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.9 million through Mar 2026, up 55.56% year-over-year, with the annual reading at $6.0 million for FY2025, 10.06% up from the prior year.
  • Accumulated Expenses hit $10.9 million in Q1 2026 for Aura Biosciences, up from $6.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $13.7 million in Q3 2025 and bottomed at $2.4 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $6.3 million, with a median of $5.5 million recorded in 2024.
  • The largest annual shift saw Accumulated Expenses plummeted 31.42% in 2024 before it surged 213.99% in 2025.
  • Aura Biosciences' Accumulated Expenses stood at $4.6 million in 2022, then skyrocketed by 72.38% to $7.9 million in 2023, then crashed by 30.79% to $5.5 million in 2024, then rose by 10.06% to $6.0 million in 2025, then skyrocketed by 80.95% to $10.9 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's Accumulated Expenses are $10.9 million (Q1 2026), $6.0 million (Q4 2025), and $13.7 million (Q3 2025).